Eikon Therapeutics, Inc. (NasdaqGS: EIKN)
Salud · Biotecnología · US
5,98 $
-0,99 % hoy · -60,1 % 1 año
Eikon Therapeutics, Inc. (NasdaqGS: EIKN) opera en la industria de biotecnología dentro del sector salud. Su valor en bolsa es de 324,03 M $ y tiene 384 empleados.
En los últimos doce meses la acción ha bajado un 60,1 % y ha cotizado entre 5,01 y 17,40.
Tweenvest puntúa a Eikon Therapeutics, Inc. en cuatro factores: calidad 43/100, valor 100/100. Su punto más fuerte es valor.
Evolución de la cotización de EIKN
Cifras clave
- Capitalización
- 324,03 M $
- Ingresos (últ. 12 m)
- —
- PER
- -0,96
- BPA
- -32,06
- Rent. por dividendo
- —
- Beta (5 años)
- —
- Máximo 52 semanas
- 17,40 $
- Mínimo 52 semanas
- 5,01 $
- Volumen medio (3 m)
- —
- Acciones en circulación
- 54,19 M
- Empleados
- 384
- Próximos resultados
- —
Sobre Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
- ISIN
- US2825641036
- Fundada en
- 2019
- Cotiza desde
- 5 feb 2026
- Bolsa
- Nasdaq Global Select
- Divisa
- USD
Otras empresas de biotecnología
| Empresa | Capitalización | Precio | Día |
|---|---|---|---|
| BioDlink International Company LimitedSEHK: 1875 | 333,92 M $ | 3,39 HK$ | +1,50 % |
| Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd.SZSE: 300313 | 330,80 M $ | 9,20 CN¥ | -3,97 % |
| IMPACT Therapeutics, IncSEHK: 7630 | 328,17 M $ | 9,12 HK$ | +8,64 % |
| GC Corp.KOSE: A005250 | 325,65 M $ | 9580,00 ₩ | -1,44 % |
| Enanta Pharmaceuticals, Inc.NasdaqGS: ENTA | 320,09 M $ | 10,99 $ | -1,87 % |
| X4 Pharmaceuticals, Inc.NasdaqCM: XFOR | 318,59 M $ | 3,12 $ | -1,58 % |
| Benitec Biopharma Inc.NasdaqCM: BNTC | 317,08 M $ | 9,09 $ | -4,01 % |
| Inovio Pharmaceuticals, Inc.NasdaqCM: INO | 316,55 M $ | 1,69 $ | +3,68 % |